Dermatology Biotech Bambusa Raises $168.9 Million in US IPO
Bambusa Therapeutics Inc., an early-stage biotech focused on dermatology and autoimmune diseases, raised $168.9 million in an upsized US initial public offering that priced at the midpoint of its marketed...
By Avalon Pernell · Bloomberg
Bambusa Therapeutics Inc., an early-stage biotech focused on dermatology and autoimmune diseases, raised $168.9 million in an upsized US initial public offering that priced at the midpoint of its marketed range.